Hypertension Grading and Treatment
Blood pressure is classified into four categories: normal (<120/<80 mm Hg), elevated (120-129/<80 mm Hg), stage 1 hypertension (130-139/80-89 mm Hg), and stage 2 hypertension (≥140/≥90 mm Hg), with treatment strategies escalating based on stage and cardiovascular risk. 1
Blood Pressure Classification Framework
The 2025 AHA/ACC guidelines establish the following grading system 1, 2:
- Normal BP: <120 mm Hg systolic AND <80 mm Hg diastolic
- Elevated BP: 120-129 mm Hg systolic AND <80 mm Hg diastolic
- Stage 1 Hypertension: 130-139 mm Hg systolic OR 80-89 mm Hg diastolic
- Stage 2 Hypertension: ≥140 mm Hg systolic OR ≥90 mm Hg diastolic
Critical caveat: When systolic and diastolic readings fall into different categories, always classify the patient into the higher stage. This "up-staging" rule is essential—systolic blood pressure alone correctly classifies approximately 96% of patients, making it the dominant factor in staging decisions 3.
Treatment Strategies by Stage
Elevated Blood Pressure (120-129/<80 mm Hg)
Lifestyle modifications only for all patients 1:
- Weight management to achieve healthy BMI
- DASH dietary pattern adoption
- Sodium reduction (<2,300 mg/day, ideally <1,500 mg/day)
- Increased dietary potassium intake
- Moderate physical activity (150 minutes/week aerobic exercise)
- Stress management techniques
- Alcohol reduction or elimination
Stage 1 Hypertension (130-139/80-89 mm Hg)
Treatment depends on cardiovascular risk stratification 1:
Immediate pharmacotherapy PLUS lifestyle modifications if patient has:
- Clinical cardiovascular disease (coronary disease, heart failure, prior stroke)
- Diabetes mellitus
- Chronic kidney disease
- 10-year PREVENT cardiovascular risk ≥7.5%
Initial 3-6 month trial of lifestyle modifications alone if:
- 10-year PREVENT cardiovascular risk <7.5%
- No diabetes, CKD, or established CVD
- If BP remains ≥130/80 mm Hg after this trial, initiate pharmacotherapy 1
Stage 2 Hypertension (≥140/≥90 mm Hg)
Immediate initiation of pharmacotherapy PLUS lifestyle modifications for all patients 1.
Preferred approach: Start with two first-line agents of different classes in a single-pill, fixed-dose combination rather than separate pills. This improves adherence and reduces time to BP control 1.
Treatment Targets
The overarching blood pressure goal is <130/80 mm Hg for all adults 1. This represents a more aggressive target than older guidelines and reflects evidence that lower BP reduces cardiovascular morbidity and mortality.
Exceptions requiring individualization:
- Patients requiring institutional care
- Limited predicted lifespan
- Pregnancy (see obstetric guidelines)
- Age >85 years or frailty
First-Line Medication Selection
For non-Black patients (including those with diabetes):
- Thiazide/thiazide-like diuretics
- ACE inhibitors
- Angiotensin receptor blockers (ARBs)
- Calcium channel blockers
For Black patients (including those with diabetes):
- Calcium channel blockers or thiazide-type diuretics preferred as initial therapy 4
For chronic kidney disease:
- ACE inhibitor or ARB to improve kidney outcomes 4
Implementation Considerations
Home blood pressure monitoring combined with multidisciplinary team-based care significantly improves control rates 1. However, avoid reliance on cuffless devices (including smartwatches) until they demonstrate greater precision and reliability.
Common pitfall: The 2025 AHA/ACC guidelines define hypertension at lower thresholds (≥130/80 mm Hg) than European guidelines (≥140/90 mm Hg) 5, 6. This creates potential confusion, but the American approach is based on continuous cardiovascular risk data showing benefit from earlier intervention in high-risk populations. Be aware that some patients classified as "stage 1 hypertension" by ACC/AHA criteria may have similar cardiovascular event rates as those with normal BP 7, emphasizing why risk stratification is crucial before initiating pharmacotherapy in this group.
Team-based care involving physicians, pharmacists, nurse practitioners, nurses, physician assistants, dieticians, and community health workers effectively addresses medication access and structural barriers to achieving BP control 1.